Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Chronic inflammatory demyelinating polyneuropathy

Launch
Not announced
Last updated
143 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

7 evidence topics · 15 sources

Summary

Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment; Sanofi states that, in people with CIDP who respond, about 70% of the response is considered incomplete. Approximately two-thirds of patients need long-term intravenous immunoglobulin, and in a US claims analysis 62% of immunoglobulin users were chronic users during the first year after the index date. Biomarkers of disease activity are lacking: in a withdrawal trial, 41% of participants withdrawn from intravenous immunoglobulin remained stable for 24 weeks, compared with 58% who continued it, and the lack of biomarkers can lead to potential overtreatment. After plasma exchange, 8 of 12 responders relapsed within 7 to 14 days of stopping. About 30% of survey respondents receiving intravenous immunoglobulin missed school or work because of infusions, and subcutaneous immunoglobulin typically requires administration once or twice a week. The Gamunex-C prescribing information carries a boxed warning for thrombosis, renal dysfunction, and acute renal failure, and states that renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous products in predisposed patients; observational studies indicate that corticosteroids carry a long-term risk of serious side effects.